Previous 10 | Next 10 |
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that four posters highlighting clinical data for COPIKTRA...
Verastem, Inc. (VSTM) Q2 2019 Earnings Conference Call August 01, 2019 04:30 PM ET Company Participants John Doyle - Vice President of Investor Relations & Finance Brian Stuglik - Chief Executive Officer Dan Paterson - President & Chief Operating Officer Rob Gagnon - Ch...
Verastem (NASDAQ: VSTM ): Q2 Non-GAAP EPS of -$0.48 beats by $0.01 ; GAAP EPS of -$0.57 misses by $0.08 . Revenue of $3.14M (-68.6% Y/Y) beats by $0.7M . Shares +4.4% . Press Release More news on: Verastem, Inc., Earnings news and commentary, Stocks on the move, Healthcare stoc...
Company Reports $3.0 Million in Net Product Revenues from COPIKTRA®; Raises Product Revenue Guidance for 2019 Cash, Cash Equivalents and Short-Term Investments of $187.3 Million as of June 30, 2019 Company to Host Conference Call Today at 4:30 PM ET Verastem, Inc. (Nasda...
Verastem Oncology ( VSTM ) recently announced that it entered into a licensing agreement with Sanofi ( SNY ) to develop and commercialize their COPIKTRA in several emerging markets; these regions include Russia, Turkey, the Middle East, and Africa. In return, Verastem will collect an upfro...
Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Brian Stuglik, a member of the Board of Directors, has...
Smith Micro Software (NASDAQ: SMSI ) +35% on Q2 results . More news on: Smith Micro Software, Inc., Monotype Imaging Holdings Inc., eHealth, Inc., Stocks on the move, Read more ...
Verastem (NASDAQ: VSTM ) inks an agreement with Sanofi (NASDAQ: SNY ) granting the latter exclusive rights to develop and commercialize COPIKTRA (duvelisib) for all oncology indications in Russia and the Commonwealth of Independent States (CIS), Turkey, the Middle East and Africa. More n...
Verastem Oncology to Receive an Upfront Payment of $5 Million USD; Then Eligible to Receive Up To $42 Million USD in Development and Sales Milestones and Double-Digit Percentage Royalties Sanofi Obtains Rights to Develop and Commercialize COPIKTRA in the Licensed Territories Veras...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...